Eligibility for (177)Lu-PSMA Therapy Depends on the Choice of Companion Diagnostic Tracer: A Comparison of (68)Ga-PSMA-11 and (99m)Tc-MIP-1404 in Metastatic Castration-Resistant Prostate Cancer

(177)Lu-prostate-specific membrane antigen-617 ((177)Lu-PSMA-617) is an effective therapy for metastatic castration-resistant prostate cancer (mCRPC), with evidence of improved survival over standard care. The VISION trial inclusion criteria required a metastatic lesion-to-liver ratio of greater tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Cook, Gary J.R., Wong, Wai-Lup, Sanghera, Bal, Mangar, Stephen, Challapalli, Amarnath, Bahl, Amit, Bassett, Paul, Leaning, Darren, Schmidkonz, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society of Nuclear Medicine 2023
Materias:
Clinical Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902859/
https://www.ncbi.nlm.nih.gov/pubmed/36302657
http://dx.doi.org/10.2967/jnumed.122.264296

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902859/
https://www.ncbi.nlm.nih.gov/pubmed/36302657
http://dx.doi.org/10.2967/jnumed.122.264296

Ejemplares similares